Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Pharmacol Ther. 2022 Feb 2;235:108114. doi: 10.1016/j.pharmthera.2022.108114

Fig. 1.

Fig. 1.

Differentiation of myeloid-derived suppressor cells in the TME. Under physiological conditions, hematopoietic progenitor cells (HPC) in the bone marrow give rise to macrophages, dendritic cells, and neutrophils. HPC differentiates into granulocyte-macrophage progenitor (GMP) after common myeloid progenitor (CMP), and then monocytic/dendritic cell precursor (MDP) and myeloblasts (MB) arise from GMP. MDP differentiates into monocytes/macrophages and dendritic cells, and MB differentiates into neutrophils. However, under pathological conditions like cancer, myeloid cells expand and differentiate into monocytic MDSCs or polymorphonuclear or granulocytic (PMN-MDSCs or G-MDSCs). MDSCs are recruited to the tumors by the same chemokines that are used in the migration of monocytes and neutrophils. In the TME, M-MDSCs differentiate into tumor-associated macrophages (TAMs) and PMN-MDSCs into tumor-associated neutrophils (TANs). The fig. is created with Biorender.com.